Streetbeat News

Regulatory

LBPH

Longboard Pharmaceuticals announced that the FDA has granted Breakthrough Therapy designation for bexicaserin, a treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 1:03 pm

RELIW

Trading halt status for RELIW was updated at 9:00:00 AM ET. The article provides information on the news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 1:00 pm

DARE

Trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:55 pm

HUMA

Humacyte shares are trading higher after the company announced it was granted Regenerative Medicine Advanced Therapy designation by the FDA for patients with advanced peripheral artery disease.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:51 pm

TSLA

Tesla's Cybertruck owners have reported several issues including battery drainage, lack of full self-driving (FSD) software, and charging infrastructure problems. Tesla has acknowledged the feedback and promised improvements. The company is ramping up production with a goal of delivering 250,000 units annually by 2025.

Portfolio Pulse from Anan Ashraf

July 01, 2024 | 12:49 pm

SAVA

Cassava Sciences shares are experiencing volatility as the company engages with the DOJ and SEC amid ongoing investigations. An Ad Hoc Committee has been empowered for an internal investigation based on SEC findings.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:47 pm

OCTO

Eightco Holdings Inc. (NASDAQ:OCTO) has been granted continued listing on the Nasdaq Capital Market, subject to meeting certain conditions by August 23, 2024. The company is seeking shareholder approval for a 1-for-5 reverse stock split to meet the minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:38 pm

ICCM

IceCure Medical Ltd. (NASDAQ:ICCM) has received FDA clearance for its next-generation XSense Cryoablation System with CryoProbes, a minimally-invasive technology for tumor destruction.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:33 pm

ALLO

Allogene Therapeutics has started patient screening for its pivotal Phase 2 ALPHA3 trial at several cancer centers. The trial aims to offer CAR T as a first-line treatment at community cancer centers, with enrollment expected to complete by the first half of 2026 and a potential BLA submission in 2027.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:31 pm

FOXO

FOXO Technologies has regained SEC compliance after filing its Form 10-Q for the quarter ended March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:30 pm